Cirrhosis

Cholelithiasis and Biliary Cirrhosis in a 28-Year-Old Man

April 29, 2017

A 28-year-old man was referred for liver transplantation for decompensated liver disease.

Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation

April 1, 2017

We compared data on disease prevalence in the population with data from liver transplantation waitlists.

Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities

Feb. 1, 2017

We conducted a phase 4, open-label study with limited exclusion criteria to evaluate the safety and efficacy of sofosbuvir and ribavirin in veterans with hepatitis C virus genotype 2 infection, and compensated cirrhosis.

Eradication of HCV in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications

Jan. 23, 2017

This MedPage Today AGA Reading Room article reviews the effects of a sustained viral response on outcomes of patients with HCV.

Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications

Jan. 2, 2017

We performed a prospective study to investigate the effects of SVR on outcomes of patients with HCV infection and compensated cirrhosis.

Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites

Jan. 2, 2017

We performed a randomized controlled trial to determine the effects of TIPS with stents covered with polytetrafluoroethylene in these patients.

Highlighted Abstracts from the International Digestive Disease Forum

Dec. 21, 2016

CGH features 104 abstracts from the 2016 meeting, which took place in Hong Kong.
Advertisement

AGA Congratulates Academy of Educators Grant Awardees

Dec. 9, 2016

Recipients will get $1,000 to fund the development of teaching materials and tools in the fields of gastroenterology or hepatology.

Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis

Nov. 22, 2016

This large cohort study showed that therapy is safe and effective in patients with compensated (CP score of A) cirrhosis.

GI Patient Education Materials at Your Fingertips

Oct. 31, 2016

As an AGA member, you have free, quick and easy access to the new AGA Patient INFO Center’s robust library of GI patient education materials.

Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial

Oct. 28, 2016

We found sofosbuvir-velpatasvir plus GS-9857 to be safe and effective for patients with HCV with or without compensated cirrhosis.

Patients With Hepatocellular Carcinoma Have Highest Rates of Wait-listing for Liver Transplantation Among Patients With End-Stage Liver Disease

Oct. 25, 2016

We found patients with HCC to be more likely to be placed on liver transplant wait lists than patients with decompensated cirrhosis.

Primary Sclerosing Cholangitis

Oct. 19, 2016

Andrea Gossard, APRN, CNP, 2016 co-course director of Principles of GI, delivers an overview talk on what you need to know about primary sclerosing cholangitis (PSC).

High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis

Sept. 27, 2016

In cirrhotic HCV GT1- or GT3-infected patients, ABT-493 plus ABT-530 with or without RBV achieved SVR12 rates of 96%–100% and was well tolerated.

Effects of Arsenic in Drinking Water on Risk of Hepatitis or Cirrhosis in Persons With and Without Chronic Viral Hepatitis

Aug. 23, 2016

Concentrations of arsenic concentration in drinking water significantly increase risk of hepatitis or cirrhosis in people without chronic viral hepatitis.

Share Your Thoughts on Quality Measures That Will Work for You

Aug. 16, 2016

It's important that AGA-developed quality measures meet the needs of practicing GIs and hepatologists.

Rates of and Reasons for Hospital Readmissions in Patients With Cirrhosis: A Multistate Population-based Cohort Study

Aug. 2, 2016

Reasons for readmission differ based on the cause of liver disease, and there are opportunities for quality improvement.

Update on the Safety Profile of Nonselective Beta Blockers

Aug. 2, 2016

CGH meta-analysis finds that NSBBs do not increase mortality in patients with cirrhosis and ascites or refractory ascites.

Poor Performance Status Is Associated With Increased Mortality in Patients With Cirrhosis

Aug. 1, 2016

We investigated the association between KPS score and mortality in patients with cirrhosis.

Nonselective B-Blockers and Survival in Patients With Cirrhosis and Ascites: A Systematic Review and Meta-analysis

Aug. 1, 2016

We performed a systematic review and meta-analysis to evaluate the effect of NSBBs on all-cause mortality in patients with cirrhosis and refractory ascites.

DDSEP® 8: Everything You Need to Succeed

July 26, 2016

Maintain professional excellence with AGA’s premier GI education resource.

Hydrazine Shows Potential as Therapy for Acute Alcoholic Liver Disease

July 5, 2016

New from CMGH: hydrazine protected mice from the damaging effects of alcohol.

Cirrhosis 101: What is Cirrhosis? (Spanish)

June 29, 2016

All Cirrhosis (Spanish)

June 29, 2016